Clinical Trial

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Study acronym: NAIO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-02-04; most recent amendment 2026-06-10.
Status change: Not Yet Recruiting → Recruiting 2023-03-24
Trial Details
NCT Number NCT05239546
Lead Sponsor University of Iowa
Conditions Colon Cancer, dMMR Colorectal Cancer
Enrollment 25 participants
Start Date 2023-03-24
Primary Completion 2028-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-12